CANbridge Pharma Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Latest Deal Type
  • Series E
  • Latest Deal Amount
  • $43M
Latest Deal Amount
  • Investors
  • 20

CANbridge Pharma General Information

Description

Developer of innovative biological drugs designed to treat critical medical conditions. The company's specialty healthcare products prevent and treat high-profile oral mucositis, breast cancer, genetic diseases, and other chronic diseases, enabling patients to access improved treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Primary Office
  • Suite 301,3F,Timeloit, No. 17 RongChuang Road
  • Chaoyang District
  • Beijing
  • China
+86 010 0000 0000

CANbridge Pharma Timeline

2017201820192020
Financing RoundFinancing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

CANbridge Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series E) 01-Dec-2020 $43M 00000 Completed Generating Revenue
5. Later Stage VC 04-Sep-2020 00000 Completed Generating Revenue
4. Later Stage VC (Series D) 18-Feb-2020 0000 00000 Completed Generating Revenue
3. Later Stage VC (Series C) 01-Apr-2019 0000 0000 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 24-May-2017 $25M $35M 0000 Completed Startup
1. Early Stage VC (Series A) 03-Dec-2014 $10M $10M 0000 Completed Startup
To view CANbridge Pharma’s complete valuation and funding history, request access »

CANbridge Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of innovative biological drugs designed to treat critical medical conditions. The company's specialty healthca
Pharmaceuticals
Beijing, China
00000
00000000000 00000

00000000

e irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excep
0000000000000
San Francisco, CA
000 As of 0000
00000
0.000 0000-00-00
000000&0 00000

0000000

te velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident
0000 000000000
Shanghai, China
000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CANbridge Pharma Competitors (43)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Principia Biopharma Formerly VC-backed San Francisco, CA 000 00000 000000&0 00000
0000000 0000000000 Venture Capital-Backed Shanghai, China 000 00000 00000000000 00000
0000 00000000000 Venture Capital-Backed Shanghai, China 00000 00000000000 00000
000000000 Formerly VC-backed South San Francisco, CA 00000 000.00 00000000000
0000000 Formerly PE-Backed Beijing, China 0000 00.000 000000000 00.000
You’re viewing 5 of 43 competitors. Get the full list »

CANbridge Pharma Executive Team (14)

Name Title Board Seat Contact Info
James Xue Ph.D Founder, Chief Executive Officer and Chairman
Glenn Hassan Chief Financial Officer & Chief Business Officer
Richard Gregory Acting Chief Scientific Officer
Carrie Cook Senior Vice President & Global Head, Business Development
Gerald Cox MD Chief Development Strategist and Interim Chief Medical Officer
You’re viewing 5 of 14 executive team members. Get the full list »

CANbridge Pharma Board Members (5)

Name Representing Role Since
Guangping Gao Ph.D CANbridge Pharma Board Member 000 0000
James Xue Ph.D CANbridge Pharma Founder, Chief Executive Officer and Chairman 000 0000
Mark Bamforth CANbridge Pharma Board Member 000 0000
Xubo Hu Qiming Venture Partners Board Member 000 0000
To view CANbridge Pharma’s complete board members history, request access »

CANbridge Pharma Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
3W Partners Capital PE/Buyout Minority 000 0000 000000 0
Casdin Capital Hedge Fund Minority 000 0000 000000 0
LYFE Capital Growth/Expansion Minority 000 0000 000000 0
SPDB International Corporation Minority 000 0000 000000 0
Summer Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 20 investors. Get the full list »